Dogwood Therapeutics, Inc.

  • About
    • Corporate Profile
    • Leadership
    • Board of Directors
    • Corporate Presentation
  • Technology
    • NaV 1.7
    • Antiviral Combination
  • Diseases
    • CINP
    • Long Covid
    • Fibromyalgia
  • Pipeline
  • Clinical Trials
    • CINP 203
  • Investors
  • News

Press Releases

Investors

Investors

  • Overview
  • News
    • Press Releases
    • Email Alerts
  • Events & Presentations
    • Events
    • Presentations
    • Shareholder Letters
    • Meeting
  • Governance
    • Overview
    • Leadership
    • Board of Directors
    • Board Committees
    • Governance Documents
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Financial & Stock Info
    • Overview
    • Quote
    • Charts
    • Historical Data
    • Analyst Coverage
  • Resources
    • Overview
    • IR Contacts
    • FAQ
    • Email Alerts
  • News

  • Press Releases
  • Email Alerts
Sep 12, 2023 7:05am EDT

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Aug 14, 2023 7:05am EDT

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Aug 10, 2023 7:05am EDT

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 09, 2023 7:05am EDT

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

Aug 03, 2023 4:05pm EDT

Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023

Jul 17, 2023 7:05am EDT

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

May 25, 2023 4:05pm EDT

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 15, 2023 7:05am EDT

Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia

May 11, 2023 7:05am EDT

Virios Therapeutics Announces First Quarter 2023 Financial Results

May 04, 2023 7:05am EDT

Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023

  • Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • Next
RSS
  • Email Alerts
  • Contacts
  • RSS News Feed

© 2025 Dogwood Therapeutics, Inc.           Terms and Conditions Privacy Policy Social Media Guidelines